Travere Therapeutics (TVTX)
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases i...
- Open
- 65.000
- High
- 65.640
- Low
- 63.340
- Prev. Close
- 63.900
- Volume
- 745.56K
- Turnover
- 48.42M
- Avg Price
- 64.947
- Bid/Ask Ratio
- -0.76%
- Amplitude
- 3.60%
- 52wk High
- 66.240
- Volume Ratio
- 0.83
- Turnover Ratio
- 0.84%
Travere Therapeutics Analyst Rating
View moreForecast & Rating
Aug 17, 2026Price forecast
$74.1413.59%
Forecast & RatingStrong buy
15analysts
- Strong buy80.00%
- Buy13.33%
- Hold6.67%
- Sell0.00%
- Strong sell0.00%
News
- Asian Corporate Newswire · 13 hours ago
Everest Medicines Reports 1H 2026 Results, Enters New Phase as Growth Accelerates and Innovation Gains Momentum
- Market Beat · 1 day ago, 05:00 AM
97,573 Shares in Travere Therapeutics, Inc. $TVTX Acquired by Rice Hall James & Associates LLC
- PUBT · Aug 13 at 06:14 PM
Travere Therapeutics posts corporate overview on rare kidney disease growth strategy, FILSPARI expansion and pipeline updates
- StockTitan · Aug 12 at 08:00 AM
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | TVTX Stock News
- Market Beat · Aug 12 at 03:24 AM
Travere Therapeutics, Inc. $TVTX Shares Bought by Quantinno Capital Management LP
- MSN · Aug 6 at 03:21 PM
This biotech dealmaker — tied to Merck, Travere — is in a profit-taking zone
